Arcus Biosciences Inc

20 sie 2026, 19:36 UTC

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 sie 2026, 19:46 UTC

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 sie 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 sie 2026, 19:16 UTC

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

14 sie 2026, 19:46 UTC

Arcus Biosciences Inc is higher today, continuing a positive trend since Thursday's close. The stock remains above its 20-day moving average.

11 sie 2026, 19:56 UTC

HC Wainwright raised Arcus Biosciences' Q3 2026 EPS estimate to -$1.00 and maintained a "Buy" rating with a price target of $45.00.

10 sie 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, continuing a strong upward trend since Monday's close, well above the 20-day moving average.

7 sie 2026, 19:36 UTC

Arcus Biosciences Inc. shares are higher today, trading within a typical range amid investor uncertainty over future monetary policy following a weak jobs report.

6 sie 2026, 20:03 UTC

Arcus Biosciences shares are higher as Wells Fargo raises its price target to $23.00 and Wedbush increases its target to $43. Trading volume is notably high.

5 sie 2026, 20:21 UTC

Arcus Biosciences reported a net loss of $91 million but exceeded revenue expectations with $41 million. Shares are higher in after-market trading.

4 sie 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, reflecting positive market sentiment amid easing inflation concerns from U.S.-Iran negotiations.

3 sie 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 lip 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 lip 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 lip 2026, 19:56 UTC

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 lip 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 lip 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 lip 2026, 19:06 UTC

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 lip 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 lip 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 lip 2026, 18:06 UTC

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.